dc.creator | Laustsen, Andreas Hougaard | |
dc.creator | Gutiérrez, José María | |
dc.creator | Knudsen, Cecilie | |
dc.creator | Johansen, Kristoffer H. | |
dc.creator | Bermúdez Méndez, Erick | |
dc.creator | Cerni, Felipe A. | |
dc.creator | Jürgensen, Jonas A. | |
dc.creator | Ledsgaard, Line | |
dc.creator | Martos Esteban, Andrea | |
dc.creator | Øhlenschlæger, Mia | |
dc.creator | Pus, Urska | |
dc.creator | Andersen, Mikael Rørdam | |
dc.creator | Lomonte, Bruno | |
dc.creator | Engmark, Mikael Gerling | |
dc.creator | Pucca, Manuela Berto | |
dc.date.accessioned | 2019-02-04T16:29:56Z | |
dc.date.available | 2019-02-04T16:29:56Z | |
dc.date.issued | 2018-05 | |
dc.identifier.citation | https://www.sciencedirect.com/science/article/pii/S0041010118301144?via%3Dihub | |
dc.identifier.issn | 0041-0101 | |
dc.identifier.uri | https://hdl.handle.net/10669/76544 | |
dc.description.abstract | Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many
advances in immunology, synthetic biology, and antibody research, different approaches and antibody
formats are being investigated for the ability to neutralize animal toxins. These different molecular
formats each have their own therapeutic characteristics. In this review, we provide an overview of the
advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks
of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic
features, propensity to cause adverse reactions, formulation, and expression for research and development
(R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the
use of human antibody formats as well as camelid heavy-domain antibody fragments due to their
compatibility with the human immune system, beneficial therapeutic properties, and the ability to
manufacture these molecules cost-effectively. | es_ES |
dc.description.sponsorship | Novo Nordisk Foundation/[16OC0019248]/NNF/Dinamarca | es_ES |
dc.description.sponsorship | Novo Nordisk Foundation/[13OC0005613]/NNF/Dinamarca | es_ES |
dc.description.sponsorship | Ministerio de Ciencia, Tecnología y Telecomunicaciones/[PEM-066-2015-II]/MICITT/Costa Rica | es_ES |
dc.description.sponsorship | Conselho Nacional de Desenvolvimento Científico e Tecnologico/[150749/2017-1]/CNPq/Brasil | es_ES |
dc.description.sponsorship | Universidad de Costa Rica/[OAICE-CAB-05-56-2016]/UCR/Costa Rica | es_ES |
dc.language.iso | en_US | es_ES |
dc.source | Toxicon, vol.146, pp. 151-175. | es_ES |
dc.subject | Antivenom | es_ES |
dc.subject | Venom | es_ES |
dc.subject | Recombinant antivenom | es_ES |
dc.subject | Antibodies | es_ES |
dc.subject | Snakebite | es_ES |
dc.subject | Scorpion sting | es_ES |
dc.subject | Spider bite | es_ES |
dc.subject | Animal envenoming | es_ES |
dc.subject | Pharmacokinetics | es_ES |
dc.subject | Pharmacodynamics | es_ES |
dc.subject | Immunogenicity | es_ES |
dc.subject | Venom neutralization | es_ES |
dc.subject | Antibody expression | es_ES |
dc.subject | Antivenom design | es_ES |
dc.subject | Adverse reactions | es_ES |
dc.subject | Neglected tropical diseases | es_ES |
dc.subject | Biotechnology | es_ES |
dc.subject | 615.946 Venenos animales | es_ES |
dc.title | Pros and cons of different therapeutic antibody formats for recombinant antivenom development | es_ES |
dc.type | artículo original | |
dc.identifier.doi | 10.1016/j.toxicon.2018.03.004 | |
dc.description.procedence | UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP) | es_ES |
dc.description.procedence | UCR::Vicerrectoría de Docencia::Salud::Facultad de Microbiología | es_ES |